AUR-101
Triple‑negative breast cancer and solid tumors
PreclinicalActive
Key Facts
Indication
Triple‑negative breast cancer and solid tumors
Phase
Preclinical
Status
Active
About Aurigene Pharmaceutical Services
Aurigene delivers AI‑enabled drug‑discovery services and a growing oncology pipeline for pharma partners.
View full company profile